HSP90 inhibitors in lung cancer: promise still unfulfilled

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Non-small cell lung cancer (NSCLC) has a poor prognosis, with a 5-year survival rate below 17%.
• NSCLC is a heterogeneous disease driven by distinct molecular alterations, including EGFR and ALK.
• Targeted therapies exist for some drivers, but many, like mutant KRAS, lack effective treatments.

Purpose of the Study:

• To review the development and profiles of Heat shock protein 90 (HSP90) inhibitors for NSCLC treatment.
• To explore HSP90 inhibitors as an alternative therapeutic strategy for NSCLC.
• To highlight the potential of HSP90 inhibitors in overcoming resistance to existing therapies.

Main Methods:

• Review of preclinical and clinical data on HSP90 inhibitors.
• Analysis of HSP90's role as a molecular chaperone for oncoproteins.
• Examination of molecular drivers in NSCLC and their therapeutic implications.

Main Results:

• HSP90 is essential for the stability of numerous driver oncoproteins in NSCLC.
• HSP90 inhibitors have shown promising preclinical and clinical results.
• Several HSP90 inhibitors have been developed over the past two decades.

Conclusions:

• HSP90 inhibitors represent a potential therapeutic strategy for NSCLC, especially for molecularly defined subsets or resistant cases.
• Targeting HSP90 may offer an effective approach where other targeted therapies are lacking.
• Further development of HSP90 inhibitors could significantly improve targeted treatment options for NSCLC patients.